|
|
|
July 17, 2006
Emphasys Announces Completion of $18.4
Million Financing
Founded in 2000, Emphasys is developing minimally
invasive therapies for patients with Chronic Obstructive
Pulmonary Disease (COPD). Emphasys treats lung hyperinflation,
the a fundamental problem in COPD, rather than airway
obstruction. We believe that Emphasys will emerge as a
leader in the new field of interventional pulmonology.
--------------------------------
Emphasys Medical, Inc., a company focused on improving
the lives of patients with emphysema and other severe
pulmonary disorders, today announced the completion of
its Series E Preferred Stock financing. Emphasys raised
$18.4 million in the round led by Cargill Ventures. Each
of the company's existing venture capital investors participated
in the round, as well as a new investor, Trellis Health
Ventures.
Emphasys recently completed enrollment in the pivotal
trial of the Zephyr(R) Endobronchial Valve for the treatment
of advanced emphysema. The Endobronchial Valves for Emphysema
Palliation Trial (VENT) enrolled the final patient in
April and expects to complete six-month follow-up by the
end of 2006.
"We are very pleased to add Cargill Ventures and
Trellis Health Ventures to the list of high-quality investors
that continue to provide enthusiastic support for Emphasys,"
said John McCutcheon, Emphasys Medical's President and
CEO. "This was a very strong financing for Emphasys
-- a clear indication of our leadership position."
Sanjiv Arora, Managing Director, Cargill Ventures, added,
"The high clinical need, large market opportunity,
and strong management track record are just some of the
reasons we found Emphasys attractive. We expect Emphasys
will be the first company in the U.S. with a minimally-invasive
treatment for emphysema. We are excited about the market
opportunity and the potential to help so many patients."
Back to News
|
|
| |
